CISATRACURIUM BESYLATE injection

Riik: Ameerika Ühendriigid

keel: inglise

Allikas: NLM (National Library of Medicine)

Toimeaine:

CISATRACURIUM BESYLATE (UNII: 80YS8O1MBS) (CISATRACURIUM - UNII:QX62KLI41N)

Saadav alates:

Civica, Inc.

Manustamisviis:

INTRAVENOUS

Retsepti tüüp:

PRESCRIPTION DRUG

Näidustused:

Cisatracurium besylate injection is indicated: Limitations of Use Cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. Risk Summary There are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies conducted in rats administered cisatracurium besylate during organogenesis (Gestational Day 6 to 15) found no evidence of fetal harm at 0.8 times (ventilated rats) the exposure from a human starting IV bolus dose of 0.2 mg/kg (see Data) . The estimated background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, r

Toote kokkuvõte:

Cisatracurium besylate injection, USP 10 mg cisatracurium per mL, is supplied as under: NDC Container Size 72572-067-10 20 mL Single-dose Vial Pack of 10's Intended only for use in the ICU. Discard unused portion. Storage Cisatracurium besylate injection, USP should be refrigerated at 2° to 8°C (36° to 46°F) in the carton to preserve potency. Protect from light. DO NOT FREEZE. Upon removal of the unused vial from refrigeration to room temperature storage conditions (25°C/77°F), use cisatracurium besylate injection within 21 days, even if re-refrigerated.

Volitamisolek:

Abbreviated New Drug Application

Toote omadused

CISATRACURIUM BESYLATE- CISATRACURIUM BESYLATE INJECTION
CIVICA, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CISATRACURIUM
BESYLATE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
CISATRACURIUM BESYLATE INJECTION.
CISATRACURIUM BESYLATE INJECTION, FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL: 1995
INDICATIONS AND USAGE
Cisatracurium besylate is a nondepolarizing neuromuscular blocker
indicated:
•
•
•
Limitations of Use
Cisatracurium besylate is not recommended for rapid sequence
endotracheal intubation due to the time
required for its onset of action (1)
DOSAGE AND ADMINISTRATION
Store cisatracurium besylate injection with the cap and ferrule intact
and in a manner that minimizes the
possibility of selecting the wrong product (2.1)
•
•
•
•
DOSAGE FORMS AND STRENGTHS
Injection:
•
CONTRAINDICATIONS
•
WARNINGS AND PRECAUTIONS
•
•
•
•
•
ADVERSE REACTIONS
The most common adverse reactions (0.1% to 0.4%) were bradycardia,
hypotension, flushing,
bronchospasm, and rash. (6.1)
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT SANDOZ INC., AT
1-800-525-8747 OR FDA
AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH.
DRUG INTERACTIONS
•
•
•
USE IN SPECIFIC POPULATIONS
•
SEE 17 FOR PATIENT COUNSELING INFORMATION.
REVISED: 11/2022
as an adjunct to general anesthesia to facilitate tracheal intubation
in adults and in pediatric patients
1 month to 12 years of age (1)
to provide skeletal muscle relaxation during surgery in adults and in
pediatric patients 2 to 12 years of
age as a bolus or infusion maintenance (1)
for mechanical ventilation in the ICU in adults (1)
Administer intravenously only by or under the supervision of
experienced clinicians familiar with drug’s
actions and possible complications (2.1)
Use only if personnel and facilities for resuscitation and life
support, and a cisatracurium besylate
antagonist are immediately available (2.1)
Use a peripheral nerve stimulator to determine adequacy of b